ViaNautis secures investment from SCI Ventures to deliver non-viral genetic medicines to cells at spinal cord injury sites

ViaNautis Bio develops polyNaut®, a non-viral delivery platform built on targeted polymer nanovesicles that carry DNA and mRNA payloads into specific cell types. Nanobody-guided targeting lets drug developers direct genetic medicines to defined cells and tissues without the payload limitations and immunogenicity associated with viral vectors.